This combination has “the potential to become a new standard first-line treatment” for well-differentiated grade 1/2 gastroenteropancreatic neuroendocrine ... % with diffuse liver metastases.

SAN FRANCISCO -- Progression-free survival (PFS) in gastroenteropancreatic neuroendocrine tumors ... such as patients with diffuse liver metastases or a Ki-67 labeling index of 5-20%, single ...

Everolimus plus lanreotide resulted in a progression-free survival of 29.7 months in patients with gastroenteropancreatic neuroendocrine ... metastatic or recurrent disease, and a Ki-67 index of 5% to ...

Patients also had a Ki-67 of 5%-20% or less than 5% with diffuse liver metastases. A total of 178 patients were randomly assigned to receive lanreotide plus everolimus (n=90) or everolimus alone ...

Use of nucleotyping and tumor stroma ratio to predict prognosis in patients with resected intestinal-type gastric cancer. A study of the homologous recombination deficiency signature (HRDSig) status ...

Large bowel and rectal neuroendocrine cancers are rare cancers. They start in the neuroendocrine cells of the large bowel (colon) or back passage (rectum). You might also hear them called ...

Clinicopathological factors related to survival in gastroenteropancreatic neuroendocrine tumors (GEP-NET): 20 years experience in the American British Cowdray Medical Center. This is an ASCO Meeting ...

A specialist doctor injects a substance such as a gel or tiny beads to block the liver's blood supply. It is also called hepatic artery embolisation. You might have it as a treatment for a ...

Cirrhosis is a condition in which scar tissue gradually replaces your healthy liver cells. It usually happens over a long period, often due to hepatitis, alcohol use disorder, or metabolic ...

T1 Tumor limited to the pancreas and size <2 cm T2 Tumor limited ... according to Sobin and Wittekind. M: Metastasis; N: Node; T: Tumor. Data from [21]. Neuroendocrine tumors have demonstrated ...